Immuneering Corporation (NASDAQ:IMRX – Get Free Report) CEO Benjamin Zeskind acquired 2,400 shares of the stock in a transaction on Tuesday, June 23rd. The shares were acquired at an average price of $4.56 per share, with a total value of $10,944.00. Following the purchase, the chief executive officer owned 2,315,252 shares in the company, valued [...]